In the later stage of treatment, high dosages of sorafenib could continuously induce the downregulation of IL-6 expression and the upregulation of HIF-1α expression, thereby continuing to downregulate the expression of PFKFB3 and inhibiting tumor growth and invasiveness. Here, HIF1A is linked to neoplasm.